Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

LVTX

LAVA Therapeutics NV (LVTX)

LAVA Therapeutics NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LVTX
DateTimeSourceHeadlineSymbolCompany
26/01/202400:07Dow Jones NewsLava Therapeutics Shares Rise as Drug Set for Test With Merck's KeytrudaNASDAQ:LVTXLAVA Therapeutics NV
17/11/202308:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
06/09/202321:11GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LVTXLAVA Therapeutics NV
23/08/202306:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
22/08/202321:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
15/08/202320:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
14/08/202321:00GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceNASDAQ:LVTXLAVA Therapeutics NV
16/06/202306:51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
14/06/202323:00GlobeNewswire Inc.LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayNASDAQ:LVTXLAVA Therapeutics NV
09/06/202306:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
08/06/202321:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
06/06/202320:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LVTXLAVA Therapeutics NV
06/06/202308:31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LVTXLAVA Therapeutics NV
02/06/202309:38Dow Jones NewsStocks to Watch: Lululemon, Lava Therapeutics, Tilly's, OncorusNASDAQ:LVTXLAVA Therapeutics NV
02/06/202306:20GlobeNewswire Inc.LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentNASDAQ:LVTXLAVA Therapeutics NV
01/06/202322:09GlobeNewswire Inc.LAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
31/05/202307:28GlobeNewswire Inc.LAVA Announces Annual Meeting of ShareholdersNASDAQ:LVTXLAVA Therapeutics NV
25/04/202306:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
12/04/202320:03Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
11/04/202321:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
10/03/202300:05GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsNASDAQ:LVTXLAVA Therapeutics NV
16/02/202323:06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
16/02/202323:00GlobeNewswire Inc.LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
09/02/202323:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceNASDAQ:LVTXLAVA Therapeutics NV
06/02/202323:07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
06/02/202323:00GlobeNewswire Inc.LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerNASDAQ:LVTXLAVA Therapeutics NV
23/01/202323:00GlobeNewswire Inc.LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
07/01/202305:07GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of New Directors to the BoardNASDAQ:LVTXLAVA Therapeutics NV
03/01/202323:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
24/12/202208:02Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:LVTXLAVA Therapeutics NV
 Showing the most relevant articles for your search:NASDAQ:LVTX